Inogen Inc
NASDAQ:INGN

  • LAST PRICE
    8.6000
  • TODAY'S CHANGE (%)
    -0.2100 (-2.3837%)
  • Bid / Lots
    6.0600/ 1
  • Ask / Lots
    9.2000/ 1
  • Open / Previous Close
    8.9800 / 8.8100
  • Day Range
    8.4600
    8.9800
  • 52 Week Range
    4.1300
    11.9800
  • Volume
    139,445

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 8, 2024

  • May 7, 2024

      Show headlines and story abstract

    • 4:29PM ET on Tuesday May 07, 2024 by MT Newswires
      Companies Mentioned: INGN
      04:29 PM EDT, 05/07/2024 (MT Newswires) -- ...

    • 4:05PM ET on Tuesday May 07, 2024 by Business Wire
      Companies Mentioned: INGN

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2024.

    • 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
      Companies Mentioned: INGN
      ====== ====== ====== ===== ===== ===== Additional financial measures Units sold 33,900 26,900 Net rental patients as of period-end 51,800 45,800 Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures (unaudited) (in thousands) Three months ended March 31, -------------------- Non-GAAP EBITDA and Adjusted EBITDA 2024 2023 ----------------------------------------- -------- -------- Net loss (GAAP) $(14,578) $(20,349) Non-GAAP adjustments: Interest income, net (1,403) (1,525) Provision (benefit) for income taxes (150) 196 Depreciation and amortization 5,265 4,086 ------- ------- EBITDA (non-GAAP) (10,866) (17,592) Stock-based compensation 2,416 3,442 Acquisition-related expenses 238 554 Restructuring-related and other charges (1) -- 1,809 Change in fair value of earnout liability 570 -- ------- ------- Adjusted EBITDA (non-GAAP) $ (7,642) $(11,787) ======= ======= Three months ended March 31, ---------------------------------------- Net Loss Diluted EPS -------------------- ------------------ Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------ -------- -------- ------ ------ Financial Results (GAAP) $(14,578) $(20,349) $(0.62) $(0.88) Non-GAAP adjustments: Amortization of intangibles 932 26 Stock-based compensation 2,416 3,442 Acquisition-related expenses 238 554 Restructuring-related and other charges (1) -- 1,809 Change in fair value of earnout liability 570 -- Income tax impact of adjustments (2) -- -- ------- ------- ------- --------- Adjusted $(10,422) $(14,518) $(0.45) $(0.63) ======= ======= ===== ===== (1) Charges represent the costs associated with workforce reductions and associated costs and other restructuring-related activities. (2) Income tax impact of adjustments represents the tax impact related to the non-GAAP adjustments listed above and reflects an effective tax rate of 0% for 2024 and 2023.

    • 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
      Companies Mentioned: INGN
      Total revenue $78,025 $72,162 $ 5,863 8.1% 7.6% ====== ====== ====== ===== ===== ===== Additional financial measures Units sold 33,900 26,900 Net rental patients as of period-end 51,800 45,800 Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures (unaudited) (in thousands) Three months ended March 31, -------------------- Non-GAAP EBITDA and Adjusted EBITDA 2024 2023 ----------------------------------------- -------- -------- Net loss (GAAP) $(14,578) $(20,349) Non-GAAP adjustments: Interest income, net (1,403) (1,525) Provision (benefit) for income taxes (150) 196 Depreciation and amortization 5,265 4,086 ------- ------- EBITDA (non-GAAP) (10,866) (17,592) Stock-based compensation 2,416 3,442 Acquisition-related expenses 238 554 Restructuring-related and other charges (1) -- 1,809 Change in fair value of earnout liability 570 -- ------- ------- Adjusted EBITDA (non-GAAP) $ (7,642) $(11,787) ======= ======= Three months ended March 31, ---------------------------------------- Net Loss Diluted EPS -------------------- ------------------ Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------ -------- -------- ------ ------ Financial Results (GAAP) $(14,578) $(20,349) $(0.62) $(0.88) Non-GAAP adjustments: Amortization of intangibles 932 26 Stock-based compensation 2,416 3,442 Acquisition-related expenses 238 554 Restructuring-related and other charges (1) -- 1,809 Change in fair value of earnout liability 570 -- Income tax impact of adjustments (2) -- -- ------- ------- ------- --------- Adjusted $(10,422) $(14,518) $(0.45) $(0.63) ======= ======= ===== ===== (1) Charges represent the costs associated with workforce reductions and associated costs and other restructuring-related activities. (2) Income tax impact of adjustments represents the tax impact related to the non-GAAP adjustments listed above and reflects an effective tax rate of 0% for 2024 and 2023.

Peers Headlines